ASX:OSL

OncoSil Medical Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume2.17 million shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive OSL News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSil Medical and its competitors with MarketBeat's FREE daily newsletter.

About OncoSil Medical

OncoSil Medical Limited, a medical device company, focuses on the development of localized treatments for pancreatic and liver cancer in Australia. Its lead product is OncoSil, a brachytherapy device that implants a pre-determined dose of beta radiation directly into cancerous tissue for the treatment of cancer. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in June 2013. OncoSil Medical Limited is headquartered in North Sydney, Australia.

ASX Small Cap Lunch Wrap: Who’s joining a cartel today?
June 7, 2021 | msn.com

Why the Oncosil (ASX:OSL) share price finished the day higher today
May 4, 2021 | msn.com

Here's Why We're Not At All Concerned With OncoSil Medical's (ASX:OSL) Cash Burn Situation
December 9, 2020 | finance.yahoo.com

Here’s why the Oncosil Medical (ASX:OSL) share price has jumped 10% today
November 5, 2020 | fool.com.au

OncoSil Medical Limited (OSL.AX)
October 24, 2020 | finance.yahoo.com

Oncosil Medical Ltd. Registered (N6A.SG)
October 16, 2020 | ca.finance.yahoo.com

The OncoSil Medical (ASX:OSL) Share Price Is Up 75% And Shareholders Are Holding On
September 10, 2020 | finance.yahoo.com

‘A compelling story’: ASX beckons for nutraceutical stock Nutritional Growth Solutions
August 24, 2020 | msn.com

OncoSil Medical Ltd.
June 6, 2020 | www.barrons.com

How Much is OncoSil Medical Limited's (ASX:OSL) CEO Getting Paid?
April 26, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange ASX
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Current SymbolASX:OSL
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.oncosil.com.au
Phone61 2 9223 3344
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$2.22 million
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow10.91
Book ValueA$0.02 per share
Price / BookN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.52 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for OncoSil Medical.

2.6 Community Rank

Outperform Votes
OncoSil Medical has received 14 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
OncoSil Medical has received 13 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
OncoSil Medical has received 51.85% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about OncoSil Medical and other stocks. Vote “Outperform” if you believe OSL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OSL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
OncoSil Medical does not currently pay a dividend.
Dividend Growth
OncoSil Medical does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OncoSil Medical insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

OncoSil Medical (ASX:OSL) Frequently Asked Questions

What stocks does MarketBeat like better than OncoSil Medical?

Wall Street analysts have given OncoSil Medical a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OncoSil Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is OncoSil Medical's next earnings date?

OncoSil Medical is scheduled to release its next quarterly earnings announcement on Tuesday, August 17th 2021.
View our earnings forecast for OncoSil Medical.

Who are OncoSil Medical's key executives?

OncoSil Medical's management team includes the following people:

Mr. Karl David Pechmann, CFO & Company Sec.
Mr. Nigel Lange, CEO, MD & Pres of EMEA
Mr. Michael Warrener, Global Sales & Marketing Director
Dr. David Charles James, Global Head of Manufacturing Operations
Mr. Charles Rowland, Pres of US Operations (Age 70)
Dr. Ralph Peters, Chief Medical Officer
Mr. David Turner, Head of Medical Affairs

Who are some of OncoSil Medical's key competitors?

Some companies that are related to OncoSil Medical include (BUX) (BUX), Australian Clinical Labs (ACL), BARD1 Life Sciences (BD1), Charles River Laboratories International (CRL), Cryosite (CTE), dorsaVi (DVL), Epigenomics (EPGNY), Eternity Healthcare (ETAH), Genetic Signatures (GSS), Genetic Technologies (GTG), Imagin Medical (IME), Imagion Biosystems (IBX), Integral Diagnostics (IDX), Lifespot Health (LSH) and Med BioGene (MBGNF).
View all of OSL's competitors.

What other stocks do shareholders of OncoSil Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSil Medical investors own include Champion Iron (CIA), Blackmores (BKL), APA Group (APA), WiseTech Global (WTC), Twitter (TWTR), Qube (QUB), The Procter & Gamble (PG) and Charter Hall Social Infrastructure REIT (CQE).

What is OncoSil Medical's stock symbol?

OncoSil Medical trades on the ASX under the ticker symbol "OSL."

How much money does OncoSil Medical make?

OncoSil Medical has a market capitalization of $0.00 and generates $2.22 million in revenue each year.

What is OncoSil Medical's official website?

The official website for OncoSil Medical is www.oncosil.com.au.

How can I contact OncoSil Medical?

The company can be reached via phone at 61 2 9223 3344.

This page was last updated on 7/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.